Description: UCI BioSci M121 covers the following topics: Antibodies, antigens, antigen-antibody reactions, cells and tissues of lymphoreticular and hematopoietic systems, and individual and collective components of cell-mediated and humoral immune response.
Hello, everybody.
We'll get started in the lecture in a minute.
Any Dodger fans out there?
All right.
I grew up in Dodger country, so I was pretty happy
to see the game yesterday.
Let's keep it up.
Okay. So today we are going to finish,
try to finish our lecture on innate immunity.
Maybe we will, maybe we won't.
Just to start off with a couple of announcements.
First is for the recordings, our friend Sean there
in the back has listened to feedback provided by me
and others, and has now re-rendered the videos
on YouTube in a different format that's more focused,
more close up on the screen
so you can see the screen better,
and also the pointer that I use.
And there's a little bit more close-ups
of me for better or for worse.
So you can try those, and again, compare them to UCI Replay.
It seems as if the audio on UCI Replay isn't so great,
but you can decide which or use both
for your studying at home.
All right.
And then the other announcement is for extension students,
you should start bringing up your paperwork for me to sign
so that when space is open in the course at the end
of the ad period that Bio Sci can add you to the class.
So, oh, the last announcement is I'm going
to post the first practice quiz this afternoon.
I'm going to include questions from the first two chapters,
the first four lectures.
They basically correspond to questions
that have been on previous exams.
And the point is to help you prepare for the exams,
to give you an idea of the content of the exams,
the format of the questions, so you know a bit more what
to expect when you actually come here
for the midterm and the final.
And a week after I post these quizzes,
I will post an answer key, so you have some time
to take the quizzes.
They're not graded.
I don't monitor who's doing them or not.
They're just downloads for you.
So you can take them at home and then look
at the key after it's posted.
All right.
With that, I will get into today's lecture.
And most of today's lecture is going to be devoted
to the complement system.
But before we get there, we need to talk about a very important
and interesting process, which is how neutrophils get
out of the bloodstream and into inflamed tissues.
And I want to start by defining the term homing.
Homing is a general term that's used in immunology
to describe the movement of some cell from the vasculature,
from the bloodstream, into a tissue.
It could be into a lymph node, like a T cell or a B cell,
homing from the blood into the lymph node.
In this case, it's a neutrophil homing from the blood
into an inflamed tissue.
It sounds like it's going home,
but it isn't necessarily where they started.
It's just the place that they're now being directed to go.
So it's a general term for movement out of the vasculature.
And the other term in that title there is diapodesis.
And we'll come back to what that means later on.
In order for a neutrophil to home to an inflamed tissue,
they have to interact with the vascular endothelium,
which basically means the cell's lining the blood vessels.
And that interaction changes during the process of homing.
And it involves a number of pairs of molecules
that are really complementary pairs of adhesion molecules.
Adhesion molecules, for this course,
are defined as cell surface proteins or the carbohydrates
that are decorating those proteins that are important
for cells to stick to each other or for cells to stick
to extracellular matrix.
There are four structural classes of these kinds
of proteins that we're going to be concerned
with in this lecture.
And the first are the selectins.
This one shown here is called L-selectin.
These, as the name implies, are lectins, which is a general term
for a protein that binds carbohydrates.
And the selectins that are involved in homing
of neutrophils have specificity for these oligosaccharides
indicated by pentagons and hexagons here
that are decorating proteins.
In this case, the protein would be on the vascular surface.
And it's a class of proteins known as vascular adressins.
So the selectin is on the neutrophil
and the vascular adressin is on the vascular endothelial cell.
And it's called an adressin because it addresses
or talks to the neutrophil and other cells coming through.
And it does throw through these carbohydrates
that are added to the protein.
So those are the first two.
And the second two classes are down here.
One are the integrins.
You may be familiar with integrins.
They're widely distributed throughout the body
in different cell types.
They are made up of alpha and beta chains.
And they often, their ligands are members of what's known
as the immunoglobulin superfamily
or IG superfamily.
So that's the fourth class.
An example is shown here.
And the integrin we're going to talk about in today's lecture
and also when we discuss T cells is called LFA1.
Again, it has two chains.
And then the immunoglobulin-like molecule
that it binds to is called ICAM1.
So again, selectins, vascular adressins, integrins,
and IG-like molecules.
They're called IG-like because they have domains
that resemble domains of antibodies
that we'll discuss in the lecture next Wednesday.
So the next figure, 233, is a figure that you will see
in every immunology or hematology textbook.
And it's a classical description of the different steps,
the four steps of neutrophils leaving the bloodstream
and going to the inflamed tissue.
And together, that process is known as extravasation,
the process of migrating
out of the blood capillaries and into tissues.
And it starts with what's known as rolling adhesion.
A lot of the other cells like red blood cells
and lymphocytes just are going through at a fast pace
as the blood flows.
Neutrophils have on their surface these carbohydrates.
And then in this example, there's selectins actually
on the surface of the vascular cells.
And what happens is that there's enough of affinity here
that the neutrophils that bump into the walls kind
of stop a little bit and then fall off and kind of roll along.
And that is called rolling adhesion.
It slows down the neutrophils, so they're going a lot slower
than other cells that are just passing through the bloodstream.
So I think I said previously that the selectin is
on the neutrophil and the vascular adressin is
on the vascular assure.
That might be true for some pairs,
but a very important process that starts all this,
the selectin is on the vascular endothelial cells.
The vascular adressin is on the neutrophil.
And there's a particular name
for the carbohydrate linkages that's shown here
that you won't have to remember for the exam.
But just so that you know when you look at this figure,
this refers to something called sialyl Lewis X. And maybe you'll
have to memorize that for the MCATs.
I don't know.
But for this class, just know that there's carbohydrates
on the proteins on the surface of the neutrophil that stick
to the selectins, and that slows them down
and they sort of roll along.
And normally, nothing will happen at that point.
What changes is the second step of type binding occurs
if there's local inflammation
and if chemokines have been released.
Now, you should remember this chemokine CXCL8,
which is released by macrophages
that have perhaps encountered a bacteria somewhere
in this tissue, and they've released the chemokine.
Some will get stuck on extracellular matrix.
Some will diffuse out and eventually make its way
to the surface, the inner surface
of the lumen of the vasculature.
And as the neutrophil rolls along, if boom,
its receptor for CXCL8,
this G-protein coupled receptor called the CXCL8 receptor,
binds to CXCL8 displayed here, then something changes.
What happens is that the integrin LFA1 changes its
affinity for ICAM-1.
So ICAM-1 was here all along.
It's this long molecule shown here in kind of orange-pink.
And before, as it was rolling along, it's not shown here,
but those interactions of LFA1
with ICAM-1 were low affinity and not enough to slow
down the neutrophils further.
But the first thing that happens
when the CXCL8 receptor binds CXCL8 is there's the signal
that increases the affinity of LFA1 for ICAM-1,
and now you get this tight binding and it stops rolling.
Okay. So then the third step is diapodesis,
which is the physical process
of actually crossing the blood vessel wall.
There are these tight junctions
in between the vascular endothelial cells, of course,
so that things don't leak out.
But the neutrophils find ways to break those junctions
and to squeeze through, and then eventually
to reach this grayish area that's diagram gray.
It's called the basement membrane.
It has proteins and lipids that form an additional barrier
to anything trying to leave the vasculature.
But the neutrophils will secrete proteases
that digest the basement membrane, allowing it
to finish the process of squeezing into the tissues.
And then it'll follow the gradient of CXCL8 and migrate
in the fourth process, migrate towards the source
of the CXCL8, which is usually a macrophage that's sensed
to bacteria and is secreting chemokines.
So rolling adhesion with selectins and vascular adressins,
tight binding through integrin Ig-like molecule,
LFA1-ICAM1, diapodesis, squeezing
through the blood vessel walls and breaking
down the basement membrane,
and then finally migration towards the source
of the chemokine and eventually towards the bacteria
or other pathogen to destroy them.
This on the right is just a picture of a neutrophil
with, again, these two lobes to the nucleus shown here.
It's an electron micrograph of a neutrophil that's
about to start squeezing through two endothelial cells.
Any questions about neutrophil homing and diapodesis?
Yeah. Sure.
Yeah, so the problem with this figure is confusing.
This is supposed to be, this is the neutrophil.
This is the vascular tissue.
It's the integrin on the neutrophil that binds
to the ICAM1 on the vascular cell.
They show the selectin being on the neutrophil
and the vascular adressin being on the endothelial cell,
but in reality, the most important pair has the selectin
on the other side on the vascular cells
and the carbohydrates on a protein on a neutrophil.
So that's why it's confusing.
There are other pairs not discussed
in this particular example where the selectins on this side.
In fact, for T cells and B cells that express L selectin,
that's the important selectin molecules on the T cell
and the vascular adressin is
on the cells lining the lymph node.
Is that cleared up?
Yeah. All right.
Are we ready for complement?
Now, every immunology professor
in the country dreads the complement lecture
because they know that the students are going to get,
they're going to hate the nomenclature and they're going
to get confused and they're going
to think it's complicated.
But let me just tell you that the complement system is more
than just a bunch of proteins with numbers.
It's absolutely essential to so many different facets
of the immune system that we really have to plow
through and understand it in order to be immunologists
and to get what really happens in immune responses.
And the more we learn about the complement system,
the more we realize it's involved in so many processes
that we didn't even imagine even a few years ago.
Nevertheless, what we'll focus
on in this lecture are the basic functions
of the complement system and how they are achieved.
So bear with me.
Stop, ask questions if you need to and be aware
that there's nothing we can do about the nomenclature.
It's been around for 20, 25 years.
Nobody has tried to change it
or if they have they've been unsuccessful.
So we are just going to go with what we have and try
to make the best of it.
The name complement comes from the part of the serum
or the plasma that complements the function of the antibody,
that improves the function of the antibody.
And it's just basically a set of soluble proteins
that are released and made by constantly by the liver
and then are present in the blood.
They get into the lymph because they get out of the vasculature
and they're present in the extracellular fluid
of all tissues, just basically ready to respond
to foreign pathogens.
And figure 2.3 shows the most important thing
that happens, the first step of complement activation
which is called complement fixation.
And basically involves cleavage of a protein called C3
so that you generate a small fragment
which recruits phagocytes along with CXCL8 and another fragment
of complement later on.
These are the most important proteins that lead
to vascular changes and recruitment of neutrophils.
But the second important part is that you get a covalent
attachment of this larger fragment known as C3b
that covalently attaches to the bacteria.
And that marks this for phagocytosis.
And that process of covering the bacteria or the other pathogens
with complement fragments is known as opsonization.
Okay, so if you go then to figure 2.5,
it shows that there are three pathways
of complement activation which all lead to the same process
of cleavage of C3 to form C3a and C3b.
And C3b being covalently bound
to the surface components of the pathogen.
The three pathways are up here shown alternative.
We'll start by talking about that.
Then the lectin pathway and the classical pathway
which is called classical because it was the first one
to be defined and studied.
But it's really the last one that comes
into play in immune response.
And we'll start to talk about the classical pathway
which can be activated by acute phase proteins
like C-reactive protein.
And later on we'll come back to it when we talk
about the functions of antibodies.
They differ in their mechanisms of pathogen recognition.
But they all converge at the same stage to cleave C3.
They all use or they use different protein complexes
to cleave C3 and these are called C3 convertases.
And we will talk about the components
of the different C3 convertases and those will be important
for you to know and to memorize.
And lastly as we'll see in the course
of an immune response the alternative pathway is the first
to act if necessary the lectin pathway will come
into play later and even later
if the pathogen hasn't been cleared then you get the acute
phase response and adaptive immune system
components which can lead to activation
of the classical pathway.
The vast majority of complement activation events occurring all
the time as you deal with potential pathogens are dealt
with by the alternative pathway and that's it.
You don't even get to these later stages.
Now the three functions of complement activation one is
recruitment of inflammatory cells like neutrophils
and new phagocytes like monocytes which will come
into the neighborhood and become macrophages.
The second is opsonization which facilitates phagocytosis
and the third is complement components can literally poke
holes or perforate the membrane of pathogens.
People get confused when they see this
because they think only the classical pathway leads
to perforation and only the alternative pathway leads
to recruitment.
Don't look at this figure that way.
All of them converge here and then all three pathways
by cleaving C3 and releasing C3a and C3b binding no matter how
you get to here all three outcomes occur.
Just want to clarify that and together these three functions
of complement lead to the death of the pathogen.
As I mentioned there are new and emerging functions of complement
that we learn about every day.
We won't focus on these unless I specifically mention them later
in the class.
So let's start with the recognition mechanisms.
I just want to make some definitions
and discuss a concept before we get started.
First thing to understand about complement is that
as with many enzymes that circulate in your blood,
the clotting factors and so on, many of these are proteases.
They're proteolytic enzymes but they circulate
in an inactive form known as a zymogen.
It has the ability to cleave itself or other proteins
but it's not active until something happens.
And C3 is interesting
because it has an internal bond called a thioester bond
which is exposed after C3 is cleaved into C3a and C3b.
It's normally buried inside the protein
and so it's not exposed to any nucleophiles but as soon
as it's exposed to a nucleophile it's very unstable.
So it's considered a high energy bond
and by far the most common enzymatic
or non-enzymatic reaction that occurs is chemical reaction is
that water that's around
through a nucleophilic attack will cleave the thioester bond
leading to a free sulfhydryl group and a carboxyl group here
and this is an inactive fragment that just floats away
and is eventually degraded.
But if the C3b with the thioester bond happens
to be close to the surface of a pathogen
that has a nucleophile either a negative
or positive type of nucleophile that leads to attack
and now you get a covalent bond, again the sulfhydryl group
but now instead of a carboxyl group from hydrolysis you get an
attachment to some chemical group
on the surface of the pathogen
and this is the covalent binding that I was talking about.
So how does the alternative pathway get started?
There's a figure in the textbook, figure 2.6
that I'm not going to go through
because I think it's kind of confusing
but to summarize this figure it's just
that C3 molecules are constantly being cleaved in the plasma
and lymph and extracellular fluids at a low rate
by something called the soluble C3 convertase.
So let's not get into those details and just look
at figure 2.4 and say however you get there you get this low
level of cleavage that's constantly happening
and then most of the C3B is hydrolyzed by water
but occasionally you get covalent attachment
to the surface here.
Now this is where things get interesting.
Here's C3B attached to the pathogen surface.
In this form it recruits another complement factor known
as factor B which once bound to C3B becomes an active protease
which will, sorry it's not an active protease,
it becomes a substrate of a protease known as factor D.
So it's already confusing but let me go through again.
C3B on the surface here will recruit factor B,
change its conformation so it can be cleaved by factor D,
again in serum plasma or lymph.
Factor D will bind and cleave factor B into two products,
large B, small B or just called BB and then BA.
BA has no further function.
It doesn't recruit phagocytes, it's just inactive
but BB stays bound to C3B.
For most of the complement fragments that we'll talk
about the large fragment has the subscript B
and the small fragment has A. So we've already seen
that with C3A, you see that again with factor B.
The large fragment is BB, the small fragment is BA.
Now you have the alternative C3 convertase, C3B, BB
and this can cleave more C3 and we'll come back
to this in a minute.
But just, this is your friend, the alternative C3 convertase,
pathogen surface, C3B molecule covalently attached
and now the BB fragment.
Together this is a very active protease which will come
across additional molecules of C3
that haven't been cleaved at all and cleave them.
Some of them will be hydrolyzed and float away but many
of those C3B molecules because it's close
to the pathogen surface will become bound
to the pathogen surface and so, and this will stay here
and continue to cleave more C3 generating a lot of C3A
to recruit phagocytes and depositing a lot more C3B.
Each of these can then recruit a factor B which is cleaved
to form its own alternative C3 convertase.
So that's how you amplify.
As soon as you get one of these molecules
and you get B, factor B cleaved
to make the alternative C3 convertase,
you can now generate a lot more C3B and each
of those can become a C3 convertase and so on.
Does that make sense?
Okay, so that's how the alternative pathway gets
started, a very low frequency event of turnover of C3 leading
to if there's a pathogen around, you'll get C3B marking
and then amplification through the alternative C3 convertase.
Now, as I said, most of the time that deals
with the bacteria along with the recruitment
of phagocytes you take care of the infection
but if there's still bacteria around
and you get an acute phase response that will lead
to production of this protein known as manospiny lectin
or MBL and that's the lectin pathway or MBL pathway.
So, this is a structure of MBL.
It binds to carbohydrates that have mannose in them
which are very common on the surface of bacteria, fungi,
protozoa and viruses and the structure is
like a bunch of flowers.
Each of these stalks here which just looks
like one chain is actually a triple helix made
from three identical polypeptides
and that's very similar to the structure of collagen
that you have in your skin and your hair.
Each MBL molecule has five or six of these and each
of them has three pathogen binding sites
or mannose binding sites.
So, there's between 15 or 18 binding sites per MBL molecule.
Now, some human cells have mannose on them but they're not
in the right geometry to allow binding of the MBL molecule.
Because it has a structure similar to collagen
and because it binds carbohydrates so it's a lectin,
collagen plus lectin means collectin.
That's how this is a member of a family of proteins known
as collectins that have those two properties
and we'll see another one in a few minutes.
So, normally this MBL molecule diffuses around together
with two proteins called MASP1 and MASP2
and not much is happening until it binds pathogen.
At that point, MASP2 gets activated
and it cleaves another complement component
called C4.
C4 is similar to C3 in that it has a high energy thioester
bond and also that when it's cleaved,
it releases a small fragment C4A and a large fragment
that can then bind to the pathogen surface.
C4A is a weak attractant to neutrophils.
It's not nearly as important as C3A
but it can have some chemoattractant ability.
But the important one is the C4B here
and through a complicated process that I'm not going
to go into, you eventually form the classical C3 convertase
and you might ask, well, why isn't the MBL C3 convertase?
As we'll see later, it's exactly the same components
as you find in the classical pathway but it's different
than the alternative.
These are proteins we didn't see before in C3BB.
Now it's C4BC2A.
And this is the classical C3 convertase and again,
I don't have time or desire to get
through all the details here.
It just adds confusion and what I think is important
in all these pathways is to know what is the convertase
that cleaves C3 which is the important step
that activates the complement cascade
and also what's the initiating step?
So we learn the initiating step for alternative.
The initiating step for MBL is the MBL molecule binding
to the mannose in the pathogen surface activating these
proteases, the mass proteases
and eventually depositing C4B which can lead to the binding
to C2A which forms the classical C3 convertase.
And now this will cleave molecules of C3
to generate C3B and C3A which again amplifies the
complement activation.
Questions so far?
Right. So now you're just the same as you were back here.
You have C3B.
It will recruit factor B, cleave by factor D
to generate the alternative convertase.
Here's a visual comparison of the classical
and the alternative C3 convertases.
They each have two proteins.
Those proteins are different.
All of these proteins are fragments
of larger complement proteins, C3, C4, C2 and B.
And you do need to know the names of these,
the alternative C3B, BB and the classical C4B, C2A.
Now in figure 238 it reminds us
that the acute phase response is produced in response to IL-6
which is produced by macrophages in response
to bacterial infection.
And that will eventually, IL-6 will find its way to the liver
and lead to the release of MBL as well as C-reactive protein
and fibrinogen which have different roles
in the immune response and wound healing.
And because it takes time to get the MBL released,
that's why the pathway becomes important later
on after the alternative pathway has initiated the response.
So the mannose-binding lectin binds to carbohydrates
on the bacterial surfaces, acts as an opsinin
and a complement activator.
And we'll come back to the C, actually we'll talk
about the C-reactive protein now.
The classical pathway was first defined in studies of antibodies
and we'll return to that in a later lecture.
But it can also be activated by C-reactive protein
which is shown here as kind of a pentagon disc here.
It's also produced in the acute phase response.
And what happens is that when C-reactive protein will bind
to certain components of pathogen surfaces,
particularly the phosphocholine component
of lipopolysaccharide.
And once it's bound to the surface,
it recruits another member
of the collectin family known as C1.
C1q is the collectin protein with the different stalks
together looking like a bunch of flowers.
It looks very similar to MBL, has similar features,
but the sequence is different.
And in fact, what C1q binds to, this is an electron micrograph
so it really does look like that in real life.
What C1q binds to is C-reactive protein, excuse me, sorry,
when it is stuck on the pathogen surface bound to phosphocholine.
Just like the MBL, C1 carries around its own proteases
and these are known as C1R and C1S, and this will lead
to cleavage of C4 and through a similar process in C4B,
you get the formation of the classical C3 convertase,
same structure here that we found with MBL.
Okay, so, sorry, my voice seems to be going out of me.
Any questions about the MBL
or C-reactive protein activating the classical pathway?
Let's talk for a moment about optimization.
Complement covers, coats the surface of bacteria
and extracellular viruses even
and that makes them more easily phagocytosed.
Without this coating, many bacteria are resistant
to phagocytosis because they don't have a lot
of TLR ligands, PAMP structures that are recognized
by neutrophils or macrophages.
But they do have these thick coatings or cell walls made
of polysaccharides which can serve as nucleophiles
to activate the alternative pathway
or they may have substances that can bind to C-reactive protein
and so this is a way of marking the cells for phagocytosis
if they're resistant to recognition
by toll-like receptors.
The textbook has a lot of details
about different complement fragments
and different receptors so you might get bogged
down if you read the text.
We're not going to emphasize all those details.
Only what I tell you in this lecture and anything that comes
up in a later lecture will be covered on the exams.
But something that's important to keep in mind especially again
for MCATs and those kinds of exams is
that there are human diseases in which there are mutations
that affect the complement system
and if you have mutations affecting C3,
you can get really severe infections.
There are other mutations affecting other complement
components that tend to cause more mild diseases
but you need all of these to really function well
and especially C3 in order to have effective immune responses.
So we've activated C3.
Besides optimization, why is this important?
How does that lead to, for example, the poking holes
in the membranes of the bacteria?
So now we need to talk about C5.
You've seen C1.
You've seen a bit of C2 and C4.
You've seen a lot of C3.
C5 is another very important component of complement.
Now when C5 is cleaved, it forms two proteins.
Again, a larger fragment C5B and a smaller fragment C5A.
C5A is just like C3A.
It's a very important chemotractant
for inflammatory cells
and causes increased vascular permeability.
C5B has other functions that we'll see in a moment
but first you need to know what is the enzyme that cleaves C5?
There are two C5 convertases.
These are protein complexes that cleave C5.
Just as there were two C3 convertases,
there are two C5 convertases.
The alternative C5 convertase is formed by one molecule
of C3 convertase that recruits a soluble not covalently bound
but soluble fragment of C3B.
So you have one C3B that's bound to the path and surface.
You have the BB fragment and then a second C3B.
So together it's called C3B2BB.
You see why we don't like the nomenclature.
I didn't make it up.
But this is the alternative C5 convertase and rather
than cleaving C3, it recognizes C5 and that leads
to production of C5B and C5A.
We will learn the classical C5 convertase later
but for now just know the C5 convertase is C3B times 2,
one of them covalently attached, one of them not
and this BB fragment.
Yeah?
What's preventing it from doing the covalent bond?
I think that this is just a C3B molecule that's been hydrolyzed
by water but it has some affinity
for the alternative C3 convertase and binds
and then once it comes together it forms a C5 convertase.
Yeah?
Another covalently bound C3B.
I think that would be too far away on the surface
and I'm not sure if that would form the C5 convertase.
Yeah?
Can this still act as a C3 convertase?
I don't think so.
I suppose if the C3B fell off because it's going
to have some on-off rate when it's off this C3 convertase
again since it's not covalently bound it's not going
to be bound all the time.
Yeah?
The C5 can be activated by either pathway.
So it's just a downstream component of complement.
Once you get C3 convertase converting C3 to C3B you will
form this alternative C5 convertase and you also
as we'll learn later you can form a classical C5 convertase.
No matter how you start the pathway you end
up at the same place which is C3 conversion
and then eventually C5 conversion.
The convergence part happens earlier at this step.
Not shown here no matter how you get
to C3 cleavage you form a C5 convertase.
There are two forms, the alternative and the classical
but either one will cause C5 conversion.
Some C5A will be involved in recruitment.
The C5B its main role is in this perforation
of pathogen membranes but all of these will lead to both of those.
Now the poking holes in the membranes
of bacteria is a really dramatic looking process visually pretty
exciting when you look at the pictures but it's actually not
that important for host defense.
There's only a few strains of bacteria which seem
to be controlled mainly
by this what's called the membrane attack complex
but nevertheless it's important to learn and it's initiated
by C5B.
Here's some C5B here.
There are actually four other components of complement
which fortunately are numbered consecutively C6,
C7, C8 and C9 and the take home message from this slide is
that C5B catalyzes or nucleates or begins the process
of insertion of all these components
into the pathogen membrane.
Through a complex process it positions all these later
terminal as they're called terminal components
of complement in a way that can begin to poke a hole
in the membrane of the pathogen
and then you get this polymerization
of C9 fragments leading to formation of a pore
and now there's no more cell wall or lipid bilayer
that can control the osmotic pressure and balance
and so water can flow into the pathogen.
Other things can flow out.
You get these holes in the membrane
and the bacteria will just explode.
So just know that these are the terminal components
of complement.
I'm not going to ask you details
about how this membrane attack complex is formed
but you do have to know the term membrane attack complex.
Here's a picture of those membrane lesions using electron
microscopy but again there's very few bacteria
that form opportunistic infections in humans or animals
that don't have the terminal components of complement.
One exception or example of a class of bacteria
that we do control with this is the Neisseria genus
that includes gonorrhea bacteria and meningitis.
So I'm not saying it's not important but a lot of bacteria
that we deal with just the other functions
of complement are sufficient to take care of them.
This just shows you some details if you're interested.
Again, I'm not going to test you on them.
These are the terminal complement components.
You probably should know that C9 is the one that polymerizes
to actually form this pore.
So we've learned about how the complement system coats the
pathogen and how it attacks certain bacteria.
What about these C3A and C5A?
It's really very similar to what we learned for the CXCL8
but there's a new term that I want to bring
in here which is anaphylatoxin.
C5A and C3A are very, very potent
at causing vascular permeability leading to fluid leakage
from the blood vessels and extravasation
of complement proteins, other plasma proteins
and also neutrophils and monocytes.
So along with CXCL8, these C3A and C5A will do this
and they're actually extremely potent at doing this
and if there's too much complement activation,
you can lead to anaphylactic reactions that are similar
to septic shock where you have loss
of blood pressure and potentially death.
So this is where we'll take our short break for today's lecture
and talk about something that is related to the world outside
of biology and university and talk about anaphylactic shock
in popular fiction and movies.
Can anybody think of a book or a movie
in which a key character was killed
through anaphylactic shock?
All right, so who's read The Da Vinci Code?
I'm disappointed, come on.
It's not one of the world's great works of literature
but if you start it, you will not put it down.
So wait until the next break, winter break, spring break,
pick up this book and say goodbye to your family
and friends for a few days.
And so one of the characters, the two main characters
who are played in the movie by Tom Hanks and Audrey Tautou
who's a French actress, he's an American anthropologist
or something like that and I don't know what she is,
just a pretty face.
But they are trying to find the mystery
of why certain people are getting killed in front
of famous paintings and one of the sources
who could tell them who the bad guy is has a peanut allergy
and before he's able to help them out, he's actually killed
through a very clever murder
where somebody drips some peanut dust into his drink.
He can't actually taste it
and within a few seconds he's dying of asphyxiation.
So this isn't because of C3A and C5A,
it's due to an allergic response and I don't know
in the movie, I only saw it once, I don't remember
if he was shot in the movie or if they did
that anaphylactic peanut allergy thing
but I thought it was a pretty clever way to murder somebody
in a way that nobody would ever trace that you did that.
Okay. Immunology in the movies.
Then back to reality and you can see
that the complement system is very powerful
and it can be very dangerous
which is what I just tried to illustrate.
So it's not surprising that the body has evolved ways to regulate
and control complement activation
and there's a very large number of complement regulatory proteins
that control and vent destruction of host cells
and also equally important, prevent depletion of C3.
If you get too much complement activation all the time
for the wrong reasons, you will run out of C3 that you need
at a site of infection.
Now there are two classes of complement regulatory proteins.
One are the plasma proteins that interact with C3B if it happens
to become attached to the surface of a host cell
and these will lead to degradation of the C3B and some
of these are called factor H and factor I
and that will limit the amount of C3B that's active
and that will deplete all the C3 that's around
and if you lack factor I, there are patients
who lack factor I, they get too much C3 convertases
and you get depletion of C3 in the blood and the lymph
and the extracellular fluid
and so they actually get frequent infections.
So on the top, they actually talk
about another protein, properitin, which I'm not going
to talk about but just as an example, the factor H
and factor I are involved in limiting the activation
on pathogen surfaces so you don't deplete the C3 but what
about preventing the killing or the optimization
of human cells, this occurs that if you happen
to get covalent attachment of C3B
and you form the alternative convertase,
a molecule called DAF or MCP are transmembrane proteins
on the surface of our host cells that interfere
with the formation or the activity of the C3 convertase.
It disrupts these C3 convertases and eventually leads
to their degradation.
Again, the details of these figures aren't important.
The concepts I want to get across are soluble factors
that limit the depletion of C3 during immune responses
and then these transmembrane proteins
that prevent your own cells from being optimized or killed
by the membrane attack complex and I've always
like this protein because it has my initials, DAF
and there's another one called CD59
which is specifically involved even if you get to that point
of starting to form the membrane attack complex,
CD59 prevents the recruitment of the C9 proteins.
So I think we're more or less on the schedule of what I expected
which is we would just barely finish the complement pathway
and have five minutes to talk about defensins
but is there any other question
about complement before I move on?
I really suggest you go back and review this because you're going
to forget this nomenclature and later on you're going
to find it to be a big burden to try to go back and remember it
if you don't study it right away.
Okay, defensins is another family of proteins
that are produced by in this case many different cells
in the body, they're small peptides
and they have antimicrobial properties.
It's a large group of them, they fall into two classes,
the alpha defensins and the beta defensins, you don't need
to remember their names but the one property I want you
to understand about them is they have amphipathic chemical
property and what that means is that the surface
of these peptides have both positively or hydrophilic regions
as well as hydrophobic regions just like detergents
that can mix with water and oil.
These are things that you can imagine can be transported
in aqueous environments but also integrate into membranes
because of this hydrophobic properties as well.
That allows them to penetrate into the membranes of microbes.
The other thing I want you to know about the alpha defensins
is that they tend to be expressed by neutrophils
and also by a specific cell type in your gut known
as the paneth cell which is near the base
of the crypt below the stem cells
and these are specialized epithelial cells that one
of their main functions is to secrete defensins
and you can see the granules here that have the defensins
that are secreted all the time.
The beta defensins tend to be expressed by epithelial cells,
especially those of the skin, the respiratory tract
and the urogenital tract and you can see that some
of them are made constitutively, some are induced by infection
but there's a large number of them
and through their slightly different structures they've
evolved to be effective at poking holes in the membranes
of different classes of pathogens.
So I think that we can stop here because the next lecture
on adaptive immunity is not going
to take the entire 50 minutes so we can squeeze in a bit
on type 1 interferons and NK cells
at the beginning on Monday.
Oh, we have a question before we go.
Now the paneth cells, I don't think that they,
so unlike the other cells in the villi,
they're not constantly dying off
and being replaced by the stem cells.
If you remember anything about physiology,
you're constantly replacing the cells lining your intestinal
walls and the stem cells are the source of those cells.
The paneth cells are long-lived cells that are at the base
of the crypt that are secreting the defensins.